Ultragenyx (RARE) legal chief receives stock award, sells shares for taxes

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical EVP and Chief Legal Officer Karah Herdman Parschauer reported both a stock grant and a related share sale. On March 1, 2026, she acquired 11,137 shares of common stock at no cost through conversion of previously granted performance stock units upon certification of performance metrics. On March 2, 2026, she sold 8,135 shares of common stock in an open-market transaction at a weighted average price of $22.80 per share, in multiple trades between $22.54 and $23.11, to cover required tax withholdings due to vesting of restricted stock units. After these transactions, she directly held 76,346 shares, including shares acquired under the company’s employee stock purchase plan and shares underlying unvested restricted stock units subject to vesting conditions.

Insider Trade Summary

Net Seller: 8,135 shares ($185,478)

Net Sell 2 txns

Insider Parschauer Karah Herdman

Role EVP and Chief Legal Officer

Sold 8,135 shs ($185K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,135	$22.80	$185K
Grant/Award	Common Stock	11,137	$0.00	--

Holdings After Transaction: Common Stock — 76,346 shares (Direct)

Footnotes (1)

1. Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics. Represents shares sold to pay required tax withholdings due to the vesting of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range Includes 73 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2025 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parschauer Karah Herdman

(Last) (First) (Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		11,137(1)	A	$0	84,408	D
Common Stock	03/02/2026		S		8,135(2)	D	$22.8(3)	76,346(4)(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics.

2. Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range

4. Includes 73 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2025

5. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

	/s/ Karah Parschauer	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Ultragenyx (RARE) report for Karah Herdman Parschauer?

Ultragenyx reported that Karah Herdman Parschauer received 11,137 common shares from performance stock units on March 1, 2026, and sold 8,135 shares on March 2, 2026. The sale was an open-market transaction used to satisfy required tax withholdings from vesting restricted stock units.

How many Ultragenyx (RARE) shares did Karah Herdman Parschauer sell and at what price?

She sold 8,135 shares of Ultragenyx common stock at a weighted average price of $22.80 per share. The trades occurred in multiple transactions within a price range of $22.54 to $23.11, primarily to pay required tax withholdings tied to vesting restricted stock units.

What stock award did Karah Herdman Parschauer receive from Ultragenyx (RARE)?

She acquired 11,137 Ultragenyx common shares at no cost on March 1, 2026. These shares resulted from previously granted performance stock units converting into common stock after the company certified that the applicable performance metrics for those awards had been achieved.

Why did Karah Herdman Parschauer sell Ultragenyx (RARE) shares on March 2, 2026?

The filing states the 8,135 shares were sold to pay required tax withholdings triggered by vesting restricted stock units. Such tax-related sales are often made automatically or systematically when equity awards vest, instead of being discretionary investment-motivated stock sales.

How many Ultragenyx (RARE) shares does Karah Herdman Parschauer hold after these transactions?

After the reported grant and tax-related sale, she directly holds 76,346 shares of Ultragenyx common stock. This total includes 73 shares acquired under the company’s employee stock purchase plan and shares underlying previously reported restricted stock units that remain subject to vesting conditions.

Were the Ultragenyx (RARE) insider sales part of a broader investment decision?

The Form 4 notes that the 8,135 shares were sold specifically to cover required tax withholdings from vesting restricted stock units. This language indicates the transaction was primarily tax-related rather than a discretionary decision to reduce her overall Ultragenyx investment exposure.